Table of Contents
Editorial
| Introducing Oncotarget |
| Mikhail Blagosklonny, and Andrei Gudkov |
| 2 |
Commentaries
| Shape-shifting and tumor suppression by PLZF |
| Robin M. Hobbs, and Pier Paolo Pandolfi |
| 3-5 |
Reviews
| Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors |
| Stefan Duensing, and Anette Duensing |
| 6-8 |
| Abstract PDF |
Research Papers
| Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation |
| Jin Shi, Minghao Sun, and Peter K. Vogt |
| 9-21 |
| Abstract PDF |
| Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance |
| Lei Shi, Siqing Wang, Maurizio Zangari, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Fang Xiao, Yinghong Liu, Ye Yang, Mohamed Salama, Guiyuan Li, Guido Tricot, and Fenghuang Zhan |
| 22-33 |
| Abstract PDF |
| Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome |
| Emmanuel Raffoux, Audrey Cras, Christian Recher, Pierre-Yves Boëlle, Adrienne de Labarthe, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Maud Victor, Sébastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Marie-Thérèse Daniel, Pierre Fenaux, Laurent Degos, Christine Chomienne, Sylvie Chevret, and Hervé Dombret |
| 34-42 |
| Abstract PDF |
Research Perspectives
| The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword |
| Michael Hölzel, Kaspar Burger, Bastian Mühl, Mathias Orban, Markus Kellner, and Dirk Eick |
| 43-47 |
| Abstract PDF |
| ID4: a new player in the cancer arena |
| Stefania Dell’Orso, Federica Ganci, Sabrina Strano, Giovanni Blandino, and Blandino Fontemaggi |
| 48-58 |
| Abstract PDF |
| A critical role for the NFkB pathway in multiple myeloma |
| Yulia Demchenko, and W. Michael Kuehl |
| 59-68 |
| Abstract PDF |
| Targeting TOR dependence in cancer |
| Matthew R. Janes, and David A. Fruman |
| 69-76 |
| Abstract PDF |
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Impact Journals LLC 2008